Entera Bio (NASDAQ:ENTX) Shares Down 8.1% – Time to Sell?

Posted by Brenda Bartman on Aug 28th, 2026

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report)’s stock price fell 8.1% during mid-day trading on Wednesday . The stock traded as low as $3.23 and last traded at $3.1890. Approximately 119,456 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 1,112,857 shares. The stock had previously closed at $3.47.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wall Street Zen raised Entera Bio to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.00.

View Our Latest Stock Analysis on ENTX

Entera Bio Stock Down 3.4%

The firm has a fifty day moving average price of $2.37 and a 200-day moving average price of $1.65. The firm has a market cap of $535.40 million, a price-to-earnings ratio of -8.80 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). Equities research analysts anticipate that Entera Bio Ltd. will post -0.34 earnings per share for the current fiscal year.

Institutional Trading of Entera Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENTX. Citadel Advisors LLC increased its stake in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after acquiring an additional 28,322 shares during the last quarter. HighTower Advisors LLC boosted its position in shares of Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after acquiring an additional 25,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after purchasing an additional 19,601 shares during the period. Jane Street Group LLC grew its holdings in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after purchasing an additional 43,536 shares during the period. Finally, Schonfeld Strategic Advisors LLC grew its holdings in Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock valued at $1,157,000 after purchasing an additional 29,629 shares during the period. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

(Get Free Report)

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.